Get Fit Bharat

Tag: Body

HomeBody

FIDELITY EMERGING MARKETS LIMITED (the 'Company')     Legal Entity Identifier: 213800HWWQPUJ4K1GS84     TRANSACTION IN OWN SHARES     The Board of the Company announces that it has bought into Treasury.     Number of shares repurchased: 12,744 Date of transaction: 10 December 2024 Average share price paid per share (GBp): 689.000 Lowest share …

Fondia Plc Company release 10.12.2024 at 6.45 p.m. EET   Fondia – Acquisition of own shares 10.12.2024   Fondia Plc   First North Finland   Date 10.12.2024 Exchange transactions Buy Share class FONDIA Amount, shares 688 Average price/share, EUR 4,917616 Total price, EUR 3383,32         The shares …

On 4 October 2024, TF Bank AB (publ) (”TF Bank” or the ”Bank”) announced that the Bank entered into a share purchase agreement (the “Share Purchase Agreement”) with Alektum Holding AB (publ) (”Alektum Holding”) and Erik Selin Fastigheter Aktiebolag (”Erik Selin Fastigheter”) regarding a transfer of a majority stake in …

Tel Aviv, Israel (December 10, 2024) – Eco Wave Power Global AB (publ) (Nasdaq: WAVE) (“Eco Wave Power” or the “Company”), a leading innovator in onshore wave energy technology, today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 300,000 American Depositary Shares …

Los Angeles, United States:  Material, a leading insights, marketing and technology company, is pleased to announce it is the recipient of the Splash Award in the “Education” category for work with INSEAD – The Business School for the World® and runner-up in the “Corporate” category for work with Stuff Limited. The …

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OR TO ANY PERSON LOCATED OR RESIDENT IN ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL OR WOULD REQUIRE REGISTRATION OR OTHER MEASURES TO DISTRIBUTE THIS ANNOUNCEMENT. EQL Pharma AB (publ) (the “Company” or “EQL”) today announces …

San Mateo, Calif., United States:   5-year follow-up from SEQUOIA study demonstrated treatment with BRUKINSA reduced the risk of progression or death by 71% compared to bendamustine-rituximab in patients with treatment-naïve CLL, further solidifying its position as the leader in new patient starts in both frontline and relapsed/refractory (R/R) CLL with …